Andrew C. von Eschenbach's most recent trade in Bausch + Lomb Corp was a trade of 20,338 Common Shares, No Par Value done . Disclosure was reported to the exchange on May 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bausch Lomb Corp | Andrew C. von Eschenbach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 20,338 | 62,086 | - | 0 | Common Shares, No Par Value | |
| Bausch Lomb Corp | Andrew C. von Eschenbach | Director | Purchase of securities on an exchange or from another person at price $ 11.76 per share. | 02 May 2025 | 1,695 | 41,748 | - | 11.8 | 19,925 | Common Shares, No Par Value |
| TriSalus Life Sciences Inc | Andrew C. von Eschenbach | Director | 13 Aug 2024 | 15,000 | 15,000 | - | - | Director stock option (right to buy) | ||
| Bausch Lomb Corp | Andrew C. von Eschenbach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 14,696 | 40,053 | - | 0 | Common Shares, No Par Value | |
| TriSalus Life Sciences Inc | Andrew C. von Eschenbach | Director | 03 Jun 2024 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | ||
| TriSalus Life Sciences Inc | Andrew C. von Eschenbach | Director | 03 Jun 2024 | 35,000 | 0 | - | - | Stock Option (right to buy) | ||
| TriSalus Life Sciences Inc | Andrew C. von Eschenbach | Director | 10 Aug 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) |